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abstract
PURPOSE Mutation testing of the key genes involved in melanoma oncogenesis is now mandatory for the
application of targeted therapeutics. However, knowledge of the mutational profile of melanoma remains largely
unknown in Brazil.
PATIENTS ANDMETHODS In this study, we assessed the mutation status of melanoma driver genesBRAF,NRAS,
TERT, KIT, and PDGFRA in a cohort of 459 patients attended at Barretos Cancer Hospital between 2001 and
2012. We used polymerase chain reaction followed by Sanger sequencing to analyze the hot spot mutations of
BRAF exon 15 (V600E), NRAS (codons 12/13 and 61), TERT (promoter region), KIT (exons 9, 11, 13, and 17),
and PDGFRA (exons 12, 14, and 18) in tumors. The mutational profile was investigated for associations with
demographic, histopathologic, and clinical features of the disease.
RESULTS The nodular subtype was most frequent (38.9%) followed by the superficial spreading subtype
(34.4%). The most frequent tumor location was in the limbs (50.0%). The mutation rates were 34.3% for TERT
and 34.1% for BRAF followed by NRAS (7.9%), KIT (6.2%), and PDGFRA (2.9%). The BRAF (P = .014) and
TERT (P = .006) mutations were associated with younger patients and with different anatomic locations,
particularly in the trunk, for the superficial spreading and nodular subtypes, respectively (P = .0001 for both).
PDGFRA mutations were associated with black skin color (P = .023) and TERT promoter mutations with an
absence of ulceration (P = .037) and lower levels of lactate dehydrogenase. There was no association between
patient survival rates and mutational status.
CONCLUSION The similar mutational profile we observe in melanomas in Brazil compared with other populations
will help to guide precision medicine in this country.
J Global Oncol. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Melanoma is a deadly disease with an increased
global incidence in recent decades.1 GLOBOCAN
estimated 287,723 new melanoma cases worldwide
and 60,712 deaths in 2018.1 The INCA (Instituto
Nacional de Câncer) estimate for Brazil was 6,260
new melanoma cases in 2018.2 Surgical resection of
early stages is usually straightforward and un-
eventful, but advanced presentations are still life
threatening and often require complex and costly
treatments.3
In the past decade, the clinical management of pa-
tients with melanoma has changed significantly with
the discovery of the high frequency of a target mutation
in the mitogen-activated protein kinase (MAPK)
pathway in this disease.4 Now patients are treated with
anti-BRAF and anti-MEK that specifically target the
pathway and inhibit its activity. The BRAF V600
mutant kinase of the MAPK pathway is present in
approximately 37%-50% of all melanomas, and the
use of this targeted therapy has become part of
standard treatment.5,6
Other newly identified molecular alterations that
characterize the genomic mutational landscape of
melanoma comprise four main groups: the BRAF
subtype, which is defined by the presence of BRAF
hot spot mutations and is related to younger patients
when BRAF occurs withMITF amplification; the RAS
subtype, which is defined by the presence of NRAS
hot spot mutations and is related to MAPK activation
and AKT3 overexpression; the NF1 subtype, which is
associated with disease in older patients and a higher
mutation burden; and the triple wild type, which is
a heterogenous subtype defined by a lack of ultra-
violet signature with higher copy number and
complex rearrangements.7 In addition to these four
main molecular subtypes of melanoma, mutations in
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high mutation frequency (approximately 50%), and their
presence is associated with lower patient survival.8
Several subtypes of melanoma arise in body parts pro-
tected from direct ultraviolet light, including uveal,
mucosal, and acral melanomas.9 Of the various sub-
types, acral melanoma is one of the rarest, accounting for
, 2% of all melanoma cases. This melanoma can occur
in the skin but exhibits unique clinical characteristics
that affect only the palms of the hands, the soles of the
feet, and the subungual area.10 The proportion of acral
melanoma is much higher in Asian and dark-skinned
individuals than in white populations.11 Those types of
melanoma have been described with patterns of mo-
lecular alteration that distinguish them from the cuta-
neous melanomas, such as a higher frequency of KIT
and PDGFRA mutations and amplifications.12 However,
the blockade of these genes has so far demonstrated
little clinical benefit.13
Melanoma has predominantly been investigated in white
populations, and few studies have addressed its mo-
lecular characterization in an ethnically diverse and in-
terbred population. Several studies have focused on the
genetic ancestry in populations from southeastern and
northern Brazil. These studies have shown that con-
siderable admixture exists in the Brazilian population,
with an ancestry proportion of approximately 60% Eu-
ropean, 20% African, 7% Native American, and 7% East
Asian.14-19 Furthermore, the EPIGEN-Brazil project
studied 6,487 Brazilians from three population-based
cohorts with different geographic and demographic
backgrounds and showed that the ancestry proportions
fluctuated in different regions.20 These findings corr-
oborate with demographic studies that have shown that
the Brazilian population is one of the most heteroge-
neous in the world as a result of 5 centuries of interethnic
mating.15
The lack of knowledge of the frequency and diversity of
these molecular changes in Brazilian patients with mela-
noma makes it difficult to evaluate the cost-benefit of
implementing targeted therapeutics in this country.
However, these treatments clearly need to be introduced
into the public health care system because a significant
number of patients would benefit from increases in sur-
vival rates and improved quality of life. In this context, we
aimed to determine the mutational frequency of BRAF,
NRAS, KIT, PDGFRA, and TERT driver genes in 459 tu-
mors from Brazilian patients with melanoma and to
evaluate the association between mutational status and
clinicopathologic features of patients in the cohort.
PATIENTS AND METHODS
This retrospective study evaluated 459 patients with
melanoma attended at Barretos Cancer Hospital from
2001 to 2012. The inclusion criteria were a diagnosis of
melanoma, presence of formalin-fixed paraffin-embedded
(FFPE) tumor tissue for analysis, and at least 1 treatment
performed at Barretos Cancer Hospital. This study was
previously approved by the institutional ethical board
(548/2011).
Patients and Clinical Data
Demographic data (age, sex, skin color, and place of
birth) and date of primary tumor and its characteris-
tics (location, histopathologic subtype, Breslow depth,
Clark level, ulceration, and mitotic rate/mm2) were
collected from medical records. The retrieved clinical
data included the presence or absence of regional
lymph node metastases and any features of distant
metastases (localization and serum lactate dehydrogenase
[LDH]).
Progression-free and melanoma-specific survivals were
calculated, and the patients were categorized according
to validated diagnostic criteria (TNM classification).
CONTEXT
Key Objective
Do Brazilian patients share the same frequencies of hot spot mutations of essential genes in melanoma development that have
been observed worldwide?
Knowledge Generated
We found that TERT promoter was the most mutated hot spot in 308 Brazilian patients with melanoma (34.3%) followed by
BRAF (34.1%), NRAS (7.9%), KIT (6.2%), and PDGFRA (2.9%). The Brazilian population has similar frequencies of
mutation for these 5 key genes to that observed in other countries. The small differences that we found could be the result of
ethnic aspects, the proportion of primary and metastatic cases included in the studies, and/or the proportion of melanoma
subtypes.
Relevance
Our study provides the relative frequencies of driver genes in melanoma development after undergoing target therapy. These
findings allow for more accurate predictions of the financial impact of the implementation of these treatment options in the
Brazilian health care system.
Vicente et al
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Survival tests were performed from the date of primary
tumor diagnosis, regional metastasis, and distant metas-
tasis to the last event (clinical evaluation or death).
DNA Isolation From FFPE Tissue
DNA was isolated from FFPE tissue sections representative
of the tumor lesions as previously described but with some
modifications. Briefly, serial adjacent 10-μm-thick un-
stained sections cut from paraffin blocks and 1 repre-
sentative hematoxylin and eosin section were analyzed by
a qualified pathologist for identification and selection of the
tumor area, which was macrodissected into a microfuge
tube using a sterile needle (Neolus 25G × 0.5 mm; Terumo
Medical Corporation, Tokyo, Japan). The macrodissected
tissue was deparaffinized by sequential washing with xylol
and ethanol (100%-70%-50%) and allowed to air dry. DNA
was extracted using a QIAamp DNA Micro Kit (QIAGEN,
Hilden, Germany) according to the manufacturer’s in-
structions and then quantified using the NanoDrop 2000
system (Thermo Fisher Scientific, Waltham, MA). DNA
samples were stored at −20°C until required for genetic
analysis. Because the melanin protein present in mela-
noma tumor cells can be copurified during DNA extraction,
and this contamination may inhibit subsequent polymerase
chain reaction (PCR) methods, we used a protocol
established by our group to remove melanin from DNA of
pigmented samples.21
Mutation Analysis of TERT, KIT, PDGFRA, BRAF, and
NRAS Hot Spot Regions
The analysis of hot spot mutations of TERT promoter re-
gions (containing the sites c.-124:C.T and c.-146:C.T),
KIT (exons 9, 11, 13, and 17), PDGFRA (12, 14, and 18),
BRAF (exon 15), and NRAS (codons 12/13 and 61) was
performed by PCR followed by direct Sanger sequencing,
as described previously by our group.22,23 Briefly, using
specific pairs of primers (Appendix Table A1), the target
regions were amplified by PCR using a Veriti PCR thermal
cycler (Applied Biosystems, Foster City, CA). We used an
initial denaturation at 95°C for 15 minutes followed by 40
cycles of 95°C denaturation for 45 seconds; specific
annealing temperature was for 90 seconds and the 72°C
elongation phase for 45 seconds followed by a 72°C final
elongation for 7 minutes. Amplification of PCR products
was confirmed by gel electrophoresis.
Sequencing PCR was performed using a BigDye Termi-
nator v3.1 Cycle Sequencing Kit (Applied Biosystems) and
a 3500xL Genetic Analyzer (Applied Biosystems). Confir-
mation of all mutations was performed by repeating the
PCR and sequencing the altered regions.
Statistical Analysis
To identify associations among demographic, clinical,
histopathologic, and molecular characteristics, the Fisher’s
exact test or χ2 test was used. Associations of variables to
cancer-specific survival were tested using the Kaplan-Meier
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method. The log-rank test was applied to evaluate the
differences between the curves. Patients with melanoma
in situ were excluded from the survival analyses. For sur-
vival tests, patients with multiple tumor samples were
considered mutated when at least 1 sample presented the
alteration. Multivariable analyses were performed with the
Cox regression method for variables that were significant in
the univariable analysis or considered to fit in the multi-
variable model. The significance level considered for all
tests was 95% (P ≤ .05).
RESULTS
Patients and Tumor Features
A summary of the clinicopathologic features of all patients
in the cohort is listed in Table 1. The mean age of the
patients was 58 years, and the majority (96.5%) were self-
described as white. The most frequent anatomic location
for the primary tumor was in the limbs (50%). Histologi-
cally, the predominant subtype was nodular melanoma
(38.9%) followed by superficial spreading (34.4%) and
acral lentiginous subtype (21.1%). The majority of pa-
tients had TNM stage II or III disease, and the most rel-
evant clinical information, such as Clark level, Breslow
depth, ulceration, and mitotic index, was related to local
advanced tumors.
Mutation Profile
The quality of samples used in this study was excellent, with
sequence data being unavailable in only 32.9% (151 of
459 patients) because of poor quality and/or DNA recovery
issues. Overall, we observed that 308 (67.1%) of 459
patients had conclusive results for BRAF mutation, 290
(63.1%) for NRAS, 213 (46.4%) for TERT promoter, 145
(31.6) for KIT, and 139 (30.2%) for PDGFRA (Table 2).
Appendix Figure A1 and Figure A2 show examples of the
sequencing profiles used to identify the different somatic
mutations studied in the cohort. We found that TERT
promoter mutations were the most frequently observed
alteration, with 34.3% of the samples (73 of 213) having
this change. We found that 20.8% had TERT promoter
mutation in the c.-124:C.T region and the remaining
79.2% in the c.-146:C.T region (Tables 2 and 3). The
second most common mutated gene was BRAF, with
34.1% of the samples (105 of 308) comprising 89.7%
V600E, 8.3% V600K, 1.0% V600M, and 1% T599I
(Tables 2 and 3). NRAS mutations were found in
TABLE 2. Molecular Profile of Patients With Melanoma According to Disease Site
Genes, No. of Total (%)
Patient Group BRAF NRAS TERT KIT PDGFRA
Primary 28 of 127 (22.0) 11 of 162 (6.8) 29 of 118 (24.6) 8 of 78 (10.3) 4 of 73 (5.5)
Lymph node 19 of 55 (34.5) 7 of 66 (10.6) 24 of 47 (51.1) 0 of 29 (0.0) 0 of 28 (0.0)
Metastasis 26 of 51 (51.0) 5 of 53 (9.4) 18 of 39 (46.2) 1 of 29 (3.4) 0 of 29 (0.0)
Recurrence 5 of 9 (55.5) 0 of 9 (0.0) 2 of 9 (22.2) 0 of 9 (0.0) 0 of 9 (0.0)
Without information 27 of 66 (40.9) — — — —
Total 105 of 308 (34.1) 23 of 290 (7.9) 73 of 213 (34.3) 9 of 145 (6.2) 4 of 139 (2.9)
TABLE 3. Characterization of Mutations in the Samples According to
the Target Genes
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approximately 8% of samples (23 of 290), with 19.0% at
codons 12/13 and 81.0% at codon 61 (Tables 2-4).
Mutations in the KIT gene were found in 6% of melanomas
(9 of 145), with 11.2% at exon 9, 44.4% at exon 11,
22.2% at exon 13, and 22.2% at exon 17 (Tables 2-4).
The least frequently mutated gene was PDGFRA, with only
3% of tumors (4 of 139) having this mutation and 60.0%
being located at exon 12, 20.0% at exon 14, and 20.0% at
exon 18 (Tables 2-4).
BRAF mutations were mutually exclusive with mutations in
NRAS. Mutations in TERT occurred with a higher frequency
together with BRAF mutations compared with the much
lower rate of co-occurrence of NRAS and TERT mutations.
Mutations in KIT and PDGFRA were rare in the cohort, and
only 1 tumor had mutations of both genes (Fig 1).
Appendix Table A2 lists the comparisons between fre-
quencies of mutation across the 5 genes in our study and
that in studies with other populations. The observed dif-
ferences can be the result of several reasons, including
ethnic aspects; the proportion of primary and metastatic
cases included in the studies; and/or the proportion of
melanoma subtypes, such as the acral and mucosal
groups.
Association of Mutation Profile and Patient
Clinicopathologic Features
We observed that patients, 50 years of age presented with
a higher frequency of mutations that affected BRAF
(P = .014) and TERT (P = .006; Table 5). BRAF and TERT
mutations are associated with different anatomic locations,
especially the trunk region and the superficial spreading
and nodular tumor types, respectively (P = .0001 for all;
Table 6). In addition, mutations in TERT were associated
with the absence of ulceration (P = .037) and LDH ≤ 400
U/L (Table 6). We found that PDGFRA mutations occurred
more frequently in patients with black skin color (P = .023;
Table 5).
Specific-cancer survival was estimated in all 459 pa-
tients, with a mean of 88.8 months (standard deviation,
3.8 months), median of 68.2 months, and rate of 51.1%
at 5 years. Characteristics such as ulceration (P = .101),
age (P = .078), mitotic index (P = .542), and LDH value
(P = .377) were not related to different survival
rates. However, TNM staging (P = .001), sex
(P = .0001), anatomic location (P = .0001), histologic
subtype (P = .0009), Clark level (P = .0001), and Breslow
depth (P = .0001) were associated with different
survival rates.
In addition, we observed that the mutation status of the 5
genes did not influence 5-year survival rates (Table 7).
Similarly, the results showed no difference in cancer-
specific survival according to mutations in target genes
and the patient/tumor characteristics (Tables 8 and 9).
Multivariable analysis demonstrated that TNM stage IV,
TABLE 4. Mutated Genes According to the Exon/Codon Location
Mutation No. (%)
BRAF
Exon 15 97 (100)
NRAS
Codons 12/13 4 (19.0)





Exon 9 1 (11.2)
Exon 11 4 (44.4)
Exon 13 2 (22.2)
Exon 17 2 (22.2)
PDGFRA
Exon 12 3 (60.0)
Exon 14 1 (20.0)








FIG 1. Mutational profile of 133 patients with melanoma.
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anatomic location, and Clark level were independently
associated with different survival rates (Table 10).
DISCUSSION
This study is important because it was previously unknown
whether the frequencies of established somatic mutations,
known to be involved in melanoma development world-
wide, are similar in Brazilian patients. Our findings are
particularly relevant because the Brazilian population has
a strong ethnic mixture from Africa, Europe, Brazil (in-
digenous), and Asia.16 In the current study, the frequency
of BRAF and TERT promoter mutations was approximately
34% of the samples, with NRAS, KIT, and PDGFRA being
approximately 8%, 6%, and 3% of samples, respectively.
Most studies conducted in other populations found higher
frequencies of BRAF and TERT promoter mutations com-
pared with our study (Appendix Table A2). Specifically, in the
case of The Cancer Genome Atlas analysis, this is probably
due to the majority of the samples being derived from
metastatic cases that are known to have higher frequencies
of mutations affecting these genes. In addition, another
source of bias in the The Cancer Genome Atlas cohort is that
the acral lentiginous melanoma subtype with lower fre-
quencies of BRAF mutations was not included. NRAS, KIT,
and PDGFRA mutations also have lower frequencies in our
cohort, and these mutational alterations are usually more
frequent in the acral subtype, as described previously.19,24,25
Many studies have shown the predominance of BRAF
mutations in young patients, which were also confirmed in
our study.7,26 In addition, we found an association between
BRAF mutations and the superficial spreading subtype
tumors that occurred at an anatomic location in the trunk.
This result agrees with that of Egberts et al,25 who found an
association between mutations in this gene and tumor
localization in the trunk. However, these authors also re-
ported an association of BRAF mutations and thin mela-
nomas and absence of ulceration, which was not observed
in our study. Thomas et al26 showed that in 812 primary
melanoma tumors, BRAF mutations were associated with
the superficial and nodular disseminated subtype as well as
demonstrated associations of this mutation with mitotic
index, which was not detected in our study. In agreement
with both studies, the presence of BRAF mutations in tu-
mors was not associated with cancer-specific survival.24,25
We found an association between mutations in TERT gene
in patients , 50 years of age. In younger patients, the
tumors were often located in the trunk, whereas this as-
sociation was demonstrated elsewhere in older patients,
with locations such as the head and neck or extremities
being more common.24 Macerola et al27 showed no re-
lationship between mutations and the presence of ulcer-
ation, but they did report an association between mitotic
index and mutation, which we did not observe in our study.
TheBRAF and TERTmutations co-occurrence was present
in some of our patients. As pointed out by Shain et al,28 the
distinct evolutionary progression of BRAF nevi and early
selection of TERT promoter mutations may explain this
observation.
A substantial increase in effective therapies for patients with
advanced melanoma in the past several years has been
significantly improving patient outcomes. On the other
hand, the costs associated with these new systemic
treatments are an important consideration, especially in
terms of future public health spending. Several studies
have shown the high costs of targeted therapy for mela-
noma treatment in different countries and the subsequent
impact on the budget of the health care system.29-34 In
a recent study, Corrêa et al29 estimated the incremental
budget impact of targeted therapy for first-line treatment of
advanced nonsurgical and metastatic melanoma com-
pared with dacarbazine treatment in the Brazilian pop-
ulation between 2018 and 2020. The costs were estimated
to be more than Brazilian real $700million over the 3 years,
which represents the annual cost for using targeted therapy
that is 18-30 times more than the cost of traditional che-
motherapy. The prevalence of the BRAF V600 mutation in
this study was estimated on the basis of data from the
scientific literature because of the absence of Brazilian
information. Our study provides the frequencies of BRAF
mutation according to cancer staging, which provides
a better prediction for a cost-effective analysis of the budget
impact of targeted therapy using national frequencies.
TABLE 5. Demographic Data of 459 Patients With Melanoma According to
Mutational Profile
BRAF, No. NRAS, No. TERT, No. KIT, No.
PDGFRA,
No.
Demographic WT Mut WT Mut WT Mut WT Mut WT Mut
Sex
Male 79 41 134 14 67 45 70 5 74 1
Female 64 28 113 7 58 27 56 4 56 3
P .658 .272 .236 1.000* .205*
Age, years
≤ 50 36 29 82 8 33 33 36 2 37 1
. 50 106 40 164 13 91 39 89 7 92 3
P .014 .658* .006 1.000* .872*
Residence
Rural 5 3 15 1 5 3 4 0 4 0
Urban 69 35 140 11 47 39 27 4 27 4
P 1.000* 1.000* .728* 1.000* 1.000*
Skin color
White 131 67 234 18 114 69 117 8 122 2
Pigmented 10 2 11 3 10 2 8 1 7 2
P .344* .088* .217* .476* .023*
NOTE. Boldface indicates significant value.
Abbreviations: Mut, mutated; WT, wild type.
*Fisher exact test.
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TABLE 6. Clinical and Tumor Characteristics of 459 Patients With Melanoma According to Mutational Profile
BRAF, No. NRAS, No. TERT, No. KIT, No. PDGFRA, No.
Characteristic WT Mut WT Mut WT Mut WT Mut WT Mut
Breslow depth, mm
≤ 1 7 5 21 0 11 4 8 0 8 0
1.1-2.0 24 10 40 2 20 13 21 1 21 1
2.1-4.0 27 20 47 6 26 16 23 5 25 3
. 4 50 19 80 9 47 19 45 3 48 0
P .327* .347* .603 .310* .088*
Mitosis/mm2
0 1 0 1 0 1 0 1 0 1 0
≤ 1 17 7 28 1 17 12 14 2 16 0
. 1 80 34 108 7 75 25 75 7 79 3
P 1.000* .511* .143* .671* 1.000*
Anatomic location
Limbs 84 26 125 11 78 23 66 8 70 4
Trunk 19 29 59 6 18 28 26 0 26 0
Head and neck 22 8 38 2 15 13 17 1 18 0
Mucosal 5 0 5 0 5 1 5 0 4 0
P .0001* .840* .0001* .303* .531*
Histologic type
Acral lentiginous 50 8 53 7 53 6 45 7 48 4
Nodular 31 22 63 6 21 23 18 1 19 0
Superficial spreading 24 23 53 3 26 19 33 1 34 0
Lentigo maligna 1 0 2 0 0 1 0 0 0 0
Mucosal 8 0 8 0 9 0 9 0 8 0
Uveal 1 0 1 0 1 0 1 0 1 0
P .0001* .710* .0001* .381* .356*
Ulceration
Present 58 20 84 8 49 19 45 6 48 3
Absent 22 16 44 2 20 19 16 2 17 1
P .072 .496* .037 1.000* 1.000*
TNM stage
In situ 0 0 2 0 0 1 0 0 0 0
I 13 8 30 0 13 10 13 0 12 1
II 49 18 82 7 49 19 47 4 49 1
III 52 29 77 10 43 25 41 4 43 2
IV 26 14 50 4 18 15 22 1 23 0
P .627 .361* .214* .848* .437*
Clark level
1 0 1 1 0 1 0 1 0 1 0
2 3 1 5 0 2 1 1 0 1 0
3 19 11 42 1 16 14 17 0 16 1
4 40 29 82 11 46 22 41 4 42 3
5 42 13 54 5 33 15 34 5 39 0
P .114* .356* .593* .484* .339*
LDH, U/L
≤ 400 47 20 61 8 52 18 61 6 65 1
. 400 35 11 43 3 37 9 43 1 41 3
P .090 .440* .001 .309* .307
NOTE. Boldface indicates significant value.
Abbreviations: LDH, lactate dehydrogenase; Mut, mutated; WT, wild type.
*Fisher exact test.
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During this research development, we faced challenges in
PCR amplification, including the presence of melanin,
which copurifies during DNA extraction and is an inhibi-
tor of DNA polymerase. Because no protocol for melanin
removal was available, we have developed a method to
solve this issue.21 We recovered many samples using our
protocol, but 151 samples could not be tested probably
because of tissue fixation issues and the long years the
samples have been stored.
Overall, Brazilian patients with melanoma have similar
frequencies of BRAF, NRAS, TERT, KIT, and PDGFRA
mutations observed in other populations, which indicates
TABLE 7. Cancer-Specific Survival of 459 Patients With Melanoma According to Mutational Status of Target Genes
Gene and Category No. 5-Year Survival Rate, % P
BRAF
WT 141 42.1 .619
Mutated 69 33.3
NRAS
WT 245 46.1 .587
Mutated 21 31.6
TERT
WT 123 45.3 .251
Mutated 72 39.5
KIT
WT 124 38.4 .898
Mutated 9 48.6
PDGFRA
WT 128 40.8 .553
Mutated 4 0.0
Abbreviation: WT, wild type.
TABLE 8. Cancer-Specific Survival of 459 Patients With Melanoma According to Mutational and Demographic Characteristics
BRAF, No. NRAS, No. TERT, No. KIT, No. PDGFRA, No.
Characteristic WT Mut WT Mut WT Mut WT Mut WT Mut
Sex
Male 78 41 133 14 66 45 69 5 73 1
Female 63 28 112 7 57 27 55 4 55 3
P .686 .660 .400 .929 .528
Age, years
≤ 50 35 29 81 8 32 33 35 2 36 1
. 50 105 40 163 13 90 39 88 7 91 3
P .511 .556 .400 .822 .547
Residence
Rural 68 35 139 11 46 39 26 4 26 4
Urban 5 3 15 1 5 3 4 0 4 0
P .502 .273 .403 NC NC
Skin color
White 129 67 232 18 112 69 115 8 120 2
Dark 10 2 11 3 10 2 8 1 7 2
P .802 .544 .863 .151 .141
Abbreviations: Mut, mutated; NC, not calculated; WT, wild type.
Vicente et al
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TABLE 9. Cancer-Specific Survival of 459 Patients With Melanoma According to Mutational Status of Target Genes and Clinical Characteristics
BRAF, No. NRAS, No. TERT, No. KIT, No. PDGFRA, No.
Characteristic WT Mut WT Mut WT Mut WT Mut WT Mut
TNM stage
I 13 8 30 0 13 10 13 0 12 1
II 47 18 80 7 47 19 45 4 47 1
III 52 29 77 10 43 25 41 4 43 2
IV 26 14 50 4 18 15 22 1 23 0
P .922 NC .148 NC NC
Breslow depth, mm
≤ 1 7 5 21 0 11 4 8 0 8 0
1.1-2.0 24 10 40 2 20 13 21 1 21 1
2.1-4.0 26 20 46 6 25 16 22 5 24 3
. 4 49 20 80 9 46 20 45 3 48 0
P .258 NC .222 NC NC
Histologic type
Acral lentiginous 48 8 51 7 51 6 43 7 46 4
Nodular 31 22 63 6 21 23 18 1 19 0
Superficial spreading 24 23 53 3 29 19 33 1 34 0
Lentigo maligna 1 0 2 0 0 1 0 0 0 0
Uveal 1 0 1 0 1 1 1 0 1 0
Mucosal 8 0 8 0 9 0 9 0 8 0
P NC NC NC NC NC
Clark level
1 0 1 1 0 1 0 1 0 1 0
2 3 1 5 0 2 1 1 0 1 0
3 18 11 41 1 14 14 16 0 15 1
4 39 29 81 11 45 22 40 4 41 3
5 42 13 54 5 33 15 34 5 39 0
P NC NC NC NC NC
Ulceration
Present 57 20 83 8 48 19 44 6 47 3
Absent 21 16 43 2 19 19 15 2 16 1
P .863 .056 .433 .702 .540
Anatomic location
Limbs 82 26 123 11 76 23 64 8 68 4
Trunk 19 29 59 6 18 28 26 0 26 0
Head and neck 22 8 38 2 15 13 17 1 18 0
Mucosal 5 0 5 0 5 1 5 0 4 0
P NC NC .276 NC NC
Abbreviations: Mut, mutated; NC, not calculated by SPSS (IBM Corporation, Chicago, IL); WT, wild type.
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that the high rate of miscegenation in Brazil is not a relevant
factor for melanoma development in our patients. More-
over, Brazil can benefit from all currently used targeted
therapies, and we are well prepared for emerging thera-
peutics directed at these more frequent mutational
groupings.
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TABLE 10. Multivariable Analysis of Melanoma-Specific Survival of 459 Patients With Melanoma
Variable No. HR 95% CI P
TNM stage
I 65 0.116 0.055 to 0.245 , .001
II 109 0.181 0.105 to 0.310 , .001
III 97 0.333 0.201 to 0.553 , .001
IV 30 1.000 — —
Anatomic location
Limbs 153 0.183 0.043 to 0.777 .021
Trunk 98 0.255 0.060 to 1.091 .065
Head and neck 48 0.344 0.078 to 1.507 .157
Mucosal 2 1.000 — —
Clark level
1 1 0.708 0.094 to 5.327 .737
2 17 0.213 0.047 to 0.959 .044
3 73 0.792 0.472 to 1.327 .376
4 135 1.000 — —
5 75 0.640 0.419 to 0.979 .040
Age 1.004 0.992 to 1.017 .474
Abbreviation: HR, hazard ratio.
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APPENDIX
BRAF (V600E)   exon 15
KIT (Ser480Phe)   exon 9
PDGFRA (Arg590Lys)   exon 12
NRAS (Q61R)   condon 61
TERT (C250T)   promoter region
FIG A1. Sequencing electropherograms. Hot spot mutations are exemplified.
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FIG A2. Lollipop plots of driver mutations identified in BRAF, NRAS, TERT, KIT, and PDGFRA. aa, amino acids.
TABLE A1. Details of the Primers Used for Sanger Mutation Analysis
Gene Primer Sequence Fragment Size, bp Annealing Temperature, °C
BRAF exon 15 Forward: 5′-AGTGGATTCGCGGGCACAGA-3′
Reverse: 5′-CAGCGCTGCCTGAAACTC-3′
254 55.0
NRAS codons 12/13 Forward: 5′-ATGACTGAGTACAAACTGGT-3′
Reverse: 5′-CTCTATGGTGGGATCATATT-3′
111 56.5
NRAS codon 61 Forward: 5′-TCTTACAGAAAACAAGTGGT-3′
Reverse: 5′-GTAGAGGTTAATATCCGCAA-3′
174 56.5
KIT exon 9 Forward: 5′-AGAGTAAGCCAGGGCTTTTG-3′
Reverse: 5′-AGACAGAGCCTAAACATCC-3′
272 58.0
KIT exon 11 Forward: 5′-CCAGAGTGCTCTAATGACTG-3′
Reverse: 5′-GGAGTTCCTTAAAGTCACTG-3′
266 58.0
KIT exon 13 Forward: 5′-CATGCGCTTGACATCAGTTT-3′
Reverse: 5′-TGACAGACAATAAAAGGCAGCTT-3′
212 58.0
KIT exon 17 Forward: 5′-GGTTTTCTTTTCTCCTCCAACC-3′
Reverse: 5′-GGATTTACATTATGAAAATCACAGG-3′
249 58.0
PDGFRA exon12 Forward: 5′-TCCAGTCACTGTGCTGCTTC-3′
Reverse: 5′-GCAAGGGAAAAGGGAGTCTT-3′
260 58.0
PDGFRA exon14 Forward: 5′-TGGTAGCTCAGCTGGACTGAT-3′
Reverse: 5′-GGGATGGAGAGTGGAGGATT-3′
245 58.0






Abbreviation: bp, base pair.
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